DRI Healthcare Trust launched an initial public offering in Canada, grossing $400m from the IPO and a concurrent private placement, to fund its operations, purchase royalties from a portfolio of 18 pharmaceutical products and pursue additional royalty deals. Even at a time when there seems to be no shortage of capital for biopharmaceutical research and development, the firm said many companies still see the proceeds from royalty deals as one of many viable ways to finance ever-increasing R&D costs.
The investment firm DRI Capital purchased DRI Healthcare in 2002, so it has seen interest in royalty deals from competing investors and potential sellers shift multiple times as financial markets have changed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
